Rhone Poulenc and Hoechst finalise pounds 21bn drugs merger
Thursday 26 November 1998
With speculation mounting that a deal is close, the two groups yesterday put out a formal statement confirming that they are in discussions about combining their life sciences businesses. The merger would create the second biggest drugs company after America's Merck leap-frogged Britain's Glaxo-Wellcome in terms of sales.
The brief statement warned however that there could be no "guarantee as to the outcome of the current discussions". The talks, which are believed to have been going on for at least six weeks, have broken off at least once. Analysts pointed out that several other deals of which Glaxo-SmithKline is the most glaring recent example have collapsed even later stage.
Rhone-Poulenc's chief executive Jean-Rene Fourtou and his team were yesterday preparing to fly out to Hoechst's Frankfurt headquarters for a series of face-to-face meetings aimed at ironing out the final details of the deal.
Rhone is being advised by Rothschild and Goldman Sachs with Morgan Stanley and Lazards advising Hoechst.
In a further effort to avoiding trampling on national sensitivities, it is believed that an outside agency has been brought in to work on a neutral name for the combined operation on the model of Novartis, the product of the Swiss Ciba-Geigy-Sandoz merger.
Observers said there were clear signs of tensions between the French and Germans, with the French unhappy at suggestions that the Germans had the upper hand in negotiations.
Hoechst chief executive Jurgen Dormann will head the management board, with Rhone's Mr Fourtou being kicked upstairs to the supervisory board. The top job at the larger drugs division has gone to Richard Markham, the American who heads up Hoechst Marion Roussel. The agro-chemical division will be based in Lyons and headed by Frenchman Alain Godard.
Hoechst is to push ahead with the plans outlined last week to spin off its industrial chemicals businesses into a new quoted company called Celanese.
Analysts are highly critical of the deal. Both companies have pursued similar strategies aimed at reducing their exposure to bulk chemicals and building up their pharmaceutical operations through acquisitions. However, neither has any blockbuster drugs in the pipeline.
"This is a merger born out of weakness," said one analyst.
- 1 Woman 'suffocates newborn baby in plastic bag and puts it in her desk minutes after giving birth'
- 2 I've been called an abusive and dangerous parent, when all I did was listen to my transgender child
- 3 Company breaks open Apple Watch to discover what it says is 'planned obsolescence'
- 4 Teaching profession headed for crisis as numbers continue to drop and working lives become 'unbearable'
- 5 Chinese student carries disabled friend to school every day for three years
Nepal earthquake in pictures: Photos show devastation caused by 7.8 magnitude earthquake
Royal baby: Live updates as superbug closes ward at St Mary's Hospital in London where Duchess of Cambridge is due to give birth
Nepal earthquake: Rescuers forced to dig with their bare hands in search for survivors as images show damage to historic buildings
Ed Miliband and Boris Johnson in angry clash live on BBC's Andrew Marr Show
Bali Nine executions: British grandmother on death row in Indonesia Lindsay Sandiford says she 'just wants to get it over with'
General Election 2015: Chuka Umunna on the benefits of immigration, humility – and his leader Ed Miliband
The sickening truth about food banks that the Tories don't want you to know
Migrant boat disaster: Ukip candidate mocks victims in sickening Twitter post
Nigel Farage wants the BBC to stop making programmes like Doctor Who, Strictly Come Dancing, and Top Gear
Global warming: Scientists say temperatures could rise by 6C by 2100 and call for action ahead of UN meeting in Paris
General Election 2015: Britain would become a 'communist dictatorship' under Ed Miliband and Nicola Sturgeon, claims wife of Michael Gove
iJobs Money & Business
£24000 - £26000 per annum + benefits : Ashdown Group: A highly successful, glo...
£50000 - £55000 per annum: Ashdown Group: Business Analyst - Financial Service...
£18000 - £23000 per annum + OTE £45K: SThree: At SThree, we like to be differe...
£20000 - £25000 per annum + competitive: SThree: Did you know? SThree is the o...